Read More

BioLineRx Entered Exclusive License Agreement To Motixafortide In Asia, Advisored By M.S.Q. Ventures; Provides $15M Upfront And Equity Investment Of $14.6M, Up To $50M In Development And Regulatory Milestones, Up To $200M In Commercial Milestones

M.S.Q. Ventures ("MSQ") is pleased to announce that its client, BioLineRx Ltd. ("BioLineRx") (NASDAQ/TASE: BLRX), has entered into an exclusive license agreement with Guangzhou Gloria Biosciences Co.,

BLRX